RESOMER RG 505 Bioresorbable PLGA Drug Delivery Grade is a poly(D,L-lactide-co-glycolide) copolymer supplied for controlled-release parenteral dosage forms and implantable drug delivery systems. The grade is defined by a nominal 50:50 molar ratio of D,L-lactide to glycolide, an ester-terminated backbone, and a nominal inherent viscosity of 0.5 dL/g measured as a 0.1% w/v solution in chloroform at 25 °C using an Ubbelohde capillary viscometer. The copolymer is amorphous; no melting endotherm is observed by differential scanning calorimetry, and the glass transition of 50:50 PLGA materials in this viscosity class is generally reported between 40 °C and 50 °C at a heating rate of 10 K/min. The granules are specified for solvent-based microsphere fabrication, hot-melt extrusion, and in situ forming depots where terminal sterilization and aseptic processing boundaries require a bioresorbable matrix with controlled degradation.

Lot release documentation for the drug delivery grade includes residual D,L-lactide, residual glycolide, residual solvent, water content, tin catalyst, and molecular weight parameters. The tin catalyst is typically stannous 2-ethylhexanoate, and its residual level is controlled because of parenteral exposure. No harmonized USP-NF monograph for poly(D,L-lactide-co-glycolide) is currently published; therefore, the polymer is released against the manufacturer’s specification and the drug product dossier. Residual solvent limits are assessed under ICH Q3C, elemental impurities under ICH Q3D, and biological safety of the final device or implant under ISO 10993-1:2018 for the intended patient contact duration. The polymer is not supplied as a sterile material; aseptic filtration of a polymer solution, gamma irradiation, or ethylene oxide exposure must be validated in the finished dosage form.

What Distinguishes RG 505 From Lower-Viscosity RG 502 and RG 503 in Syringeable Formulation Design?

The primary distinction across the 50:50 PLGA grade series is inherent viscosity, which reflects molecular weight differences and controls organic-phase viscosity, solvent removal rate, and degradation time. RG 502 carries a nominal 0.2 dL/g, RG 503 a nominal 0.3 dL/g, RG 504 a nominal 0.4 dL/g, and RG 505 a nominal 0.5 dL/g; the H-suffixed versions replace the ester end group with a carboxylic acid. The higher inherent viscosity of RG 505 reduces water penetration and suppresses initial drug diffusion in microsphere formulations, but it also increases the pressure required for tangential flow filtration and syringe extrusion. For a given concentration in dichloromethane, RG 505 solutions have substantially higher dynamic viscosity than RG 502 solutions; this can reduce particle coalescence during solvent extraction but requires higher torque in rotor-stator homogenizers and larger pump head volumes in continuous flow systems.

Compared with 75:25 and 85:15 PLGA grades, the 50:50 composition of RG 505 degrades more rapidly because the higher glycolide content increases hydrophilicity and susceptibility to ester hydrolysis. The distinction is relevant when a long-acting product requires a release interval of 3 months versus 6 months; 50:50 PLGA typically degrades faster than 75:25 PLGA under identical incubation conditions. The choice between RG 505 and a higher-lactide grade is driven by the target release interval, the drug’s acid lability, and the injection volume constraint.

The H-suffixed analogue RG 505 H carries a free carboxylic acid end group and interacts more strongly with cationic peptides and amine-containing drugs. This can increase drug loading but may also accelerate polymer degradation by increasing hydrophilicity. The ester-terminated RG 505 is selected when lower initial polymer-drug electrostatic interaction is required or when a more neutral degradation profile is preferred. The difference in end-group chemistry is quantified by acid number or titration, and the certificate of analysis lists the acid value when the H grade is supplied. For ester-terminated RG 505, residual free acid is lower than in the H grade, but the exact value varies by lot.

In continuous solvent-extraction microsphere manufacturing, the organic phase containing RG 505 and the active pharmaceutical ingredient is dispersed into an aqueous poly(vinyl alcohol) or polyvinylpyrrolidone continuous phase using a rotor-stator homogenizer or membrane emulsifier. The organic phase is commonly prepared at 5% w/w to 20% w/w polymer in dichloromethane; at the upper end of this range, the viscosity of RG 505 solutions can exceed the pressure capacity of peristaltic pumps and require gear pumps or syringe pumps with larger internal diameter tubing. Solvent extraction is performed under controlled stirring; rapid extraction solidifies the particle shell and prevents drug crystals from migrating to the surface, while excessively fast solvent removal can trap residual dichloromethane in the polymer core. Residual solvent after drying is controlled under ICH Q3C Class 2 limits for the intended route of administration and is quantified by gas chromatography with headspace sampling. Particle size distribution is measured by laser diffraction according to ISO 13320:2020 and reported as D10, D50, and D90 values. Long-acting injectable microspheres commonly exhibit D50 values between 20 μm and 80 μm; sub-10 μm fractions must be evaluated for phagocytosis and injection-site tolerability. The lower inherent viscosity of RG 502 or RG 503 reduces homogenizer pressure and heat generation, but increases the fraction of sub-10 μm particles that may be cleared by macrophages before the intended release interval is achieved.

For hot-melt extrusion, RG 505 is processed at barrel set points below 120 °C in many peptide and small-molecule formulations, with melt temperature monitored at the die. A twin-screw extruder with an L/D ratio of at least 25:1 provides distributive mixing; residence time is limited because hydrolytic chain scission accelerates with moisture and thermal stress. Pre-drying under vacuum at 25 °C to 40 °C for 24 h to 48 h is used to reduce water content below 0.5% before melt processing. Processing in ambient relative humidity above 60% without dry-air purge can cause batch-to-batch torque drift and molecular weight loss, particularly in formulations containing hygroscopic peptides. Melt pressure and torque are recorded continuously; a progressive decrease in melt pressure at constant screw speed often indicates polymer degradation rather than improved flow. Such batches require gel permeation chromatography, moisture analysis, and residual monomer testing before release.

For aseptic filtration of polymer solutions, RG 505 can be dissolved in dichloromethane or acetone at concentrations suitable for membrane filtration. The solution viscosity at 0.5 dL/g may require filtration through 0.22 μm filters with a glass fiber prefilter or elevated trans-membrane pressure. Sterile filtration of higher-viscosity grades is more difficult than with RG 502, but the sterile filtrate can be sprayed or lyophilized to recover the polymer. If filtration is not feasible, terminal sterilization of the finished microsphere or implant is required. Compatibility of the filter membrane with methylene chloride or N-methyl-2-pyrrolidone must be verified before scale-up.

Gamma Irradiation, Molecular Weight Loss, and Cold-Chain Boundaries for Packaged Granules

If terminal sterilization by gamma irradiation is applied to packaged PLGA granules, dose mapping must account for radical-induced chain scission and possible crosslinking. Published data for RG 505 under all irradiation configurations is limited; however, studies on comparable 50:50 PLGA materials indicate that absorbed doses above 25 kGy reduce inherent viscosity and can increase the initial release phase because lower molecular weight accelerates water penetration. Gamma irradiation at 25 kGy to 40 kGy is common for medical devices, but the polymer granules may require storage at 2 °C to 8 °C after irradiation to suppress post-irradiation radical chemistry. Electron-beam sterilization may produce less thermal damage at equivalent dose but requires thinner package penetration and may not reach all granule regions. Dose selection is supported by ISO 11137-1:2006 and ISO 11137-2:2013 for bioburden or sterility assurance level. The irradiated polymer should be characterized by gel permeation chromatography, residual monomer, moisture, and glass transition before use. A specification for post-irradiation molecular weight retention should be established in the device or drug product dossier rather than assumed from unirradiated granules.

Drug release from RG 505 matrices is controlled by water uptake, polymer hydration, and ester hydrolysis. In aqueous media at 37 °C and pH 7.4, 50:50 PLGA degrades faster than 75:25 or 85:15 PLGA because the glycolide-rich sequence increases hydrophilicity and ester hydrolysis. Release often follows a triphasic profile: initial diffusion from surface-associated drug, a slow lag phase during polymer hydration, and a rapid erosion phase associated with autocatalytic bulk degradation and mass loss. The autocatalytic effect is more pronounced in large implants and microspheres with diameters above 100 μm, where acidic degradation products accumulate in the core and lower the internal pH. In vitro release testing is commonly performed using USP <711> apparatus 4 for microspheres or apparatus 2 with a dialysis adapter; the selection must be justified by sink conditions and drug stability. In vivo, the degradation products D,L-lactic acid and glycolic acid are metabolized and cleared, but local pH depression at the injection site is possible with high-dose depots. For peptide-loaded microspheres, adsorption and acylation interactions with PLGA degradation products can reduce drug integrity; therefore, reversed-phase HPLC and mass spectrometry are required during stability studies.

If N-Methyl-2-Pyrrolidone Is Used as a Solvent in In Situ Implants, What Phase Inversion Boundary Must Be Observed?

In situ forming implants based on RG 505 are prepared by dissolving the polymer and drug in a water-miscible solvent such as N-methyl-2-pyrrolidone. Upon injection into an aqueous physiological environment, the solvent diffuses out and water diffuses in, causing phase inversion and precipitation of the polymer-drug depot. With RG 505, polymer concentrations below 20% w/w in NMP may produce fragmented or soft depots with high initial drug release because the polymer-poor phase does not solidify rapidly enough to restrict diffusion. Concentrations between 30% w/w and 50% w/w are often used to form cohesive depots; however, the resulting organic-phase viscosity is substantially higher than with RG 502 or RG 503 and may require a 21-gauge or larger needle to remain injectable. NMP is classified as ICH Q3C Class 2 and must be controlled in the finished drug product; the acceptable daily exposure depends on the route and clinical duration. Phase inversion is monitored by rheometry, cloud-point measurement, and scanning electron microscopy of the precipitated depot. Because RG 505 is amorphous, the depot remains a glassy or rubbery mass rather than a crystalline network; mechanical integrity depends on solvent exchange rate and polymer molecular weight. Published data for this specific configuration is limited, so depot hardness and in vivo release should be confirmed in the target animal model.

Regulatory alignment for this polymer is achieved through the following standards and guidance documents.

Storage of RESOMER RG 505 should be maintained in tightly closed containers under inert gas or dry conditions at 2 °C to 8 °C for long-term stability; the polymer is hygroscopic and will undergo hydrolytic degradation if exposed to moisture. Repeated opening of the container under ambient humidity increases water uptake and reduces molecular weight. After each use, the container should be resealed under vacuum or nitrogen purge.